Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment
Título del documento: Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment
Revista: Annals of hepatology
Base de datos: PERIÓDICA
Número de sistema: 000417624
ISSN: 1665-2681
Autors: 1
1
2
Institucions: 1Universidad de Chile, Hospital Clínico, Santiago de Chile. Chile
2Universidad Andrés Bello, Facultad de Ciencias Biológicas, Santiago de Chile. Chile
Any:
Període: Nov-Dic
Volum: 11
Número: 6
Paginació: 827-837
País: México
Idioma: Inglés
Tipo de documento: Revisión bibliográfica
Enfoque: Analítico
Resumen en inglés Hepatitis C virus (HCV) is an important global health problem with an estimated prevalence of more than 170 million infected individuals worldwide. Currently, the standard antiviral therapy, based on pegylated interferon alpha and ribavirin, can achieve a virological response in only nearly 50% of the patients infected with HCV genotype 1, the most widely distributed globally. During the last years, relevant data from genome-wide association studies (GWAS) about the impact and contribution of the patient genomics on viral infection outcomes has suggested the possibility that an individualized antiviral therapy can be considered. In this review, we analyze the existing information on single nucleotide polymorphisms (SNPs) of several host genes and viral factors that influence, as a whole, the outcome of the standard antiviral therapy, and that might be used to predict an individualized antiviral response. We also discuss the clinical data within the most recent context of the triple antiviral therapy
Disciplines Medicina
Paraules clau: Gastroenterología,
Terapéutica y rehabilitación,
Genética,
Polimorfismo,
Variación genética,
Terapia antiviral,
Respuesta antiviral,
Peginterferón,
Ribavirina,
Hepatitis C,
Virus de la hepatitis C
Keyword: Gastroenterology,
Therapeutics and rehabilitation,
Genetics,
Polymorphism,
Antiviral therapy,
Genetic variation,
Antiviral response,
Peginterferon,
Ribavirin,
Hepatitis C,
Hepatitis C virus
Text complet: Texto completo (Ver PDF)